Sequantrix GmbH

SequantrixTM was created by leading pioneers in fibrosis research, clinical care and computational science to address the large, unmet medical need for anti-fibrotic therapies.

Our approach starts with the systematic discovery and validation of novel, anti-fibrotic targets by leveraging some of the world’s largest human multi-modal, single-cell datasets in the field of fibrotic diseases.

Our aim is to develop anti-fibrotic drug candidates up to the clinical proof of concept. We have identified several novel anti-fibrotic targets of high biological relevance and will swiftly move to drug candidate development.